GRI Bio, Inc.

NasdaqCM:GRI

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 3.02 M

Share Price

USD 1.27

Avg Daily Volume

497,880

Change (1 day)

-0.78%

Change (1 year)

Change (YTD)

-86.17%

GRI Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending December 31, 2024

GRI Bio, Inc. Revenue Per Share is NA for the Trailing 12 Months (TTM) ending December 31, 2024. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

GRI Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending December 31, 2022 was USD 0.00.
GRI Bio, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending December 31, 2021 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio

NasdaqCM: GRI

GRI Bio, Inc.

CEO	Dr. W. Marc Hertz Ph.D.
IPO Date	Feb. 10, 2021
Location	United States
Headquarters	2223 Avenida de la Playa
Employees	3
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.